EPISEEK™ Multi-Cancer Detection
Invest in your patients’ health.
The Precision Epigenomics liquid biopsy test, EPISEEK™, is a groundbreaking multi-cancer detection (MCD) test that uses a simple blood draw to identify DNA changes associated with over 60 types of cancer. By detecting hypermethylated DNA loci—areas commonly hypermethylated across various cancers—EPISEEK™ enables early, accurate detection, even in individuals without prior signs of cancer.
Using advanced technology software, epigenomic modifications are analyzed. This technology is cost-effective, precise, and minimally invasive, and it may detect cancer earlier than imaging. It is also more accessible than a tissue biopsy.
The EPISEEK™ Tests Detects All Major Cancer Types
Brain
Lung & Bronchus
Breast
Colon & Rectum
Prostate
Bladder
Kidney
Pancreas
Uterine and Cervical
Lymphoma
Myeloma & Leukemia
Thyroid
Oral
Liver
Esophagus
Ovarian
Skin
Feel in Control of Your Health
Talk to your healthcare professional about scheduling your EPISEEK™ multi-cancer detection test.
%
5-Year Survival Rate
when cancer is detected early*
*The American Cancer Society
The Right Provider Is Committed to Keeping You Healthy
“As a physician, I know that early detection is critical in the fight against cancer. The EPISEEK™ liquid biopsy test is a groundbreaking tool that identifies cancer at its earliest stages, when it’s most treatable. I highly recommend Precision Epigenomics for its accuracy and its potential to save lives by catching cancer before symptoms begin. Not only do I order EPISEEK™ for my patients, but my healthcare provider also ordered it for me.”
– KRISTINE ROMINE, MD
More Than Just an Earlier Cancer Detection Test
It’s peace of mind.
Using a specificity of 99%, EPISEEK™ is predicted to have a positive predictive value (PPV) of 40% and a negative predictive value (NPV) of 99% in patients 50 years and older.
For aggressive stages I and II cancers that do not have widely adopted screening—such as bladder, esophagus, liver, head and neck SCC, lung, pancreas, stomach, and uterine—EPISEEK™ has a sensitivity of 57%. For stage III cancer, which is still operable in many cases, the sensitivity is 73%.